These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 39050737

  • 21. Trend of cost and utilization of COPD medication in Korea.
    Lee J, Lee JH, Kim JA, Rhee CK.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():27-33. PubMed ID: 28031708
    [Abstract] [Full Text] [Related]

  • 22. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM, Thomas EC.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
    [Abstract] [Full Text] [Related]

  • 23. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2020 Apr; 157(4):846-855. PubMed ID: 31759966
    [Abstract] [Full Text] [Related]

  • 24. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy.
    Bengtson LGS, DePietro M, McPheeters J, Fox KM.
    Ther Adv Respir Dis; 2018 Apr; 12():1753466618772750. PubMed ID: 29737943
    [Abstract] [Full Text] [Related]

  • 25. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K, Silva Miguel L, Hillas G, Borges M, Papageorgiou G, Viana D, Malhadeiro J, Soulard S.
    Ther Adv Respir Dis; 2020 Apr; 14():1753466620926802. PubMed ID: 32519591
    [No Abstract] [Full Text] [Related]

  • 26. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
    Liao PA, Pan SW, Chen CY, Deng CY, Dong YH.
    Int J Chron Obstruct Pulmon Dis; 2023 Apr; 18():553-563. PubMed ID: 37069844
    [Abstract] [Full Text] [Related]

  • 27. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD.
    Strange C, Walker V, DePietro M, Tong J, Kurlander J, Carlyle M, Millette LA, Wittbrodt E.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr; 14():1377-1388. PubMed ID: 31303751
    [Abstract] [Full Text] [Related]

  • 28. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice.
    Ding B, Kallenbach L, Slipski L, Wilk A, O'Brien D, Guranlioglu D.
    Int J Chron Obstruct Pulmon Dis; 2020 Apr; 15():775-786. PubMed ID: 32346288
    [Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.
    Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.
    Int J Chron Obstruct Pulmon Dis; 2018 Apr; 13():3867-3877. PubMed ID: 30568438
    [Abstract] [Full Text] [Related]

  • 30. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
    Kew KM, Dahri K.
    Cochrane Database Syst Rev; 2016 Jan 21; 2016(1):CD011721. PubMed ID: 26798035
    [Abstract] [Full Text] [Related]

  • 31. Time-to-first exacerbation, adherence, and medical costs among US patients receiving umeclidinium/vilanterol or tiotropium as initial maintenance therapy for chronic obstructive pulmonary disease: a retrospective cohort study.
    Slade D, Ray R, Moretz C, Germain G, Laliberté F, Shen Q, Duh MS, Mahendran M, Hahn B.
    BMC Pulm Med; 2021 Jul 31; 21(1):253. PubMed ID: 34332555
    [Abstract] [Full Text] [Related]

  • 32. Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β2-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England.
    Czira A, Requena G, Banks V, Wood R, Tritton T, Castillo CM, Yeap J, Wild R, Compton C, Rothnie KJ, Herth F, Quint JK, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2023 Jul 31; 18():643-659. PubMed ID: 37155496
    [Abstract] [Full Text] [Related]

  • 33. Prescription patterns and effectiveness of medications for chronic obstructive pulmonary disease: A retrospective study of real-world settings.
    Park HJ, Lee JU, Jeon S, Lee HS, Kim BY, Chae YJ, Kim GO, Park JW, Lee JH.
    PLoS One; 2024 Jul 31; 19(6):e0304362. PubMed ID: 38857214
    [Abstract] [Full Text] [Related]

  • 34. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH.
    Int J Chron Obstruct Pulmon Dis; 2019 Jul 31; 14():1539-1548. PubMed ID: 31371939
    [Abstract] [Full Text] [Related]

  • 35. Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Dual Therapy in a Primary Care Setting in England.
    Requena G, Banks V, Czira A, Wood R, Tritton T, Wild R, Compton C, Duarte M, Ismaila AS.
    Int J Chron Obstruct Pulmon Dis; 2022 Jul 31; 17():1781-1795. PubMed ID: 35983168
    [Abstract] [Full Text] [Related]

  • 36. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017 Jul 31; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

  • 37. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database.
    Quint JK, Montonen J, Esposito DB, He X, Koerner L, Wallace L, de la Hoz A, Miravitlles M.
    Adv Ther; 2021 May 31; 38(5):2249-2270. PubMed ID: 33721209
    [Abstract] [Full Text] [Related]

  • 38. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 39. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 06; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 40. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: A U.S. database study.
    Nagar S, Patel J, Stanford RH.
    Manag Care; 2018 May 06; 27(5):40-47. PubMed ID: 29763411
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.